Enhanced radiation dermatitis associated with concurrent palliative radiation and vemurafenib therapy.
Department of Dermatology, Stanford University Medical Center and Cancer Institute, California, USA.
Karen Y
KY
Kuo
Department of Dermatology, Stanford University Medical Center and Cancer Institute, California, USA.
Wen
W
Jiang
Dermatology Service, VA Palo Alto Health Care System and Department of Dermatology, Stanford University Medical Center and Cancer Institute, California, USA.
Susan M
SM
Swetter
Bernice Y
BY
Kwong
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D002081:Buttocks; D059248:Chemoradiotherapy / Q000009:adverse effects*; D006119:Groin; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D010166:Palliative Care; D011855:Radiodermatitis / Q000209:etiology*; D012878:Skin Neoplasms / Q000473:pathology*; D013449:Sulfonamides / Q000009:adverse effects*; D013848:Thigh; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib